Structure of the transgene and PERK activation in skeletal muscles of HSA-Fv2E-PERK Tg mice.
(A) Schema of the transgene for skeletal muscle-specific expression of Fv2E-PERK. (B) Representative PCR genotyping results from wild-type (WT) and HSA-Fv2E-PERK Tg mice. (C) Representative immunoblots of phosphorylated Fv2E-PERK (P), Fv2E-PERK (non P), phosphorylated eIF2α (P), and total eIF2α (non P) in the gastrocnemius muscles of WT and HSA-Fv2E-PERK Tg mice 8 h after intraperitoneal injections of vehicle or the artificial ligand AP21087 (AP) at 0.1 mg/kg body weight (BW). (D) RT-qPCR analyses of the expression of mRNA encoding targets of eIF2α phosphorylation in HSA-Fv2E-PERK Tg and WT mice at 8 h after administration of vehicle or AP (0.1 mg/kg BW). Data are presented as means ± standard errors of the mean (SEM; n = 3–5), and differences among AP-treated HSA-Fv2E-PERK Tg mice, vehicle-treated HSA-Fv2E-PERK Tg mice, and AP-treated WT mice were considered significant at *p < 0.05 or **p < 0.01.